

USSN 10/727,092
Response to Restriction Requirement

RECEIVED
CENTRAL FAX CENTER

MAR 06 2007

Remarks


The Examiner has required restriction of the invention into the following groups of claims:

- I. Claims 1-8, to the extent that they are drawn to a method of treating allergic response comprising administering an IL-1 receptor, classified in class 514, subclass 12.
- II. Claims 1-8, to the extent that they are drawn to a method of treating allergic response comprising administering a TNF receptor, classified in class 514, subclass 12.
- III. Claims 9-11, drawn to a method of testing an indeterminate pharmaceutical for anti-allergic properties, classified in class 424, subclass 9.2.
- IV. Claims 12-18, to the extent that they are drawn to a composition comprising an IL-1 receptor, classified in class 530, subclass 350.
- V. Claims 12-18, to the extent that they are drawn to a composition comprising a TNF receptor, classified in class 530, subclass 350.

Applicants hereby elect **Group V**, without traverse.

If there are any issues which could be resolved by way of a teleconference, the Examiner is invited to telephone the undersigned representative of the Applicants to discuss the same.

Respectfully submitted,



Kathleen Fowler
Attorney for Applicants
Registration no. 40,611
Phone: (206) 265-7847
Date: March 06, 2007

Immunex Corporation
Law Department
1201 Amgen Court West
Seattle, WA 98119-03105
Telephone (206) 265-7000